ReviewCardiovascular research2021
Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect.
Review in Cardiovascular research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- B lymphocytes and hyperglycemia synergistically exacerbate coronary in-stent restenosis.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Association of the triglyceride-glucose-body mass index with all-cause mortality in critically ill patients with hemorrhagic stroke: a retrospective cohort study from the MIMIC-IV database.Neurosurgical review · 2026Article
- Identification of NR4A2 as a Potential Predictive Biomarker for Atherosclerosis.Combinatorial chemistry & high throughput screening · 2026Article
- Exploring Mechanisms of Ephx2 in Treating Atherosclerosis Using Independent Cascade Model and Adverse Outcome Pathways.Combinatorial chemistry & high throughput screening · 2026Article
- Resolution Pharmacology: State-of-the-art and therapeutic landscape.Pharmacological reviews · 2025Review
- Isoorientin Ameliorates Macrophage Pyroptosis and Atherogenesis by Reducing KDM4A Levels and Promoting SKP1-Cullin1-F-box E3 Ligase-mediated NLRP3 Ubiquitination.Inflammation · 2025Article
- Resolvin D2 limits senescent cell accumulation in atherosclerotic plaques.Vascular pharmacology · 2025Article
- Article
- The Metabolite Indole-3-Acetic Acid of Bacteroides Ovatus Improves Atherosclerosis by Restoring the Polarisation Balance of M1/M2 Macrophages and Inhibiting Inflammation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- NINJ1 and MMP9: potential biomarkers for intracranial atherosclerosis plaque vulnerability.Frontiers in neurology · 2025Article
- Leukotrienes E4 and B4 and vascular endothelium - New insight into the link between vascular inflammation and peripheral arterial.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Targeting Unc5b in macrophages drives atherosclerosis regression and pro-resolving immune cell function.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The beneficial health effects of puerarin in the treatment of cardiovascular diseases: from mechanisms to therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Inflammation and Atherosclerosis: Prospects for Clinical Trials.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- Macrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy.Circulation research · 2024Article
- Homocysteine promotes atherosclerosis through macrophage pyroptosis via endoplasmic reticulum stress and calcium disorder.Molecular medicine (Cambridge, Mass.) · 2023Article
- Association of Long Noncoding RNA Expression Signatures with Stress-Induced Myocardial Perfusion Defects.Biomolecules · 2023Article
- Vascular Inflammatory Markers as Predictors of Peripheral Arterial Disease Patients' Quality-of-Life Changes after Endovascular Treatment.Journal of clinical medicine · 2023Article
- Pathogenesis of Extraarticular Manifestations in Rheumatoid Arthritis-A Comprehensive Review.Biomedicines · 2023Review
- New Bisabolane-Type Sesquiterpenoids fromMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The resolution of inflammation (or inflammation-resolution) is an active and highly coordinated process. Inflammation-resolution is governed by several endogenous factors, and specialized pro-resolving mediators (SPMs) are one such class of molecules that have robust biological function. Non-resolving inflammation is associated with a variety of human diseases, including atherosclerosis. Moreover, non-resolving inflammation is a hallmark of ageing, an inevitable process associated with increased risk for cardiovascular disease. Uncovering mechanisms as to why inflammation-resolution is impaired in ageing and in disease and identifying useful biomarkers for non-resolving inflammation are unmet needs. Recent work has pointed to a critical role for balanced ratios of SPMs and pro-inflammatory lipids (i.e. leucotrienes and/or specific prostaglandins) as a key determinant of timely inflammation resolution. This review will focus on the accumulating findings that support the role of non-resolving inflammation and imbalanced pro-resolving and pro-inflammatory mediators in atherosclerosis. We aim to provide insight as to why these imbalances occur, the importance of ageing in disease progression, and how haematopoietic function impacts inflammation-resolution and atherosclerosis. We highlight open questions regarding therapeutic strategies and mechanisms of disease to provide a framework for future studies that aim to tackle this important human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.